Compare Amphastar Pharmaceuticals Inc (AMPH) vs Chart Industries Inc (GTLS) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

GTLS trades at $209.87, up 0.13% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported $4.26B revenue in 2025 but missed EPS estimates for three consecutive quarters, with negative net income margin and ROE. Recent news highlights Baker Hughes' pending $13.6B acquisition, which secured EU antitrust approval in July 2026, providing a significant catalyst.

The stock's outlook is supported by strong analyst buy ratings (54%) and the acquisition premium, but risks include consistent earnings misses, profitability challenges, and integration execution. Valuation appears stretched with a P/E of 629.67, suggesting cautious optimism hinges on deal completion and margin improvement.